CRSPNEUTRAL

Gross Margin

-3346.4%

Higher than 0% of Healthcare sector peers

Updated 1078h ago

Sector Performance

0th percentile

CRSP

-3346.4%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

A gross margin of -3346.4% means that CRISPR Therapeutics' cost of goods sold far exceeds its revenue—for every dollar of sales, the company loses over $33, making its core product production deeply unprofitable.

The healthcare sector median gross margin is 69.4%, and the company sits at the 0th percentile among peers, meaning every other company in the sector reports a higher gross margin. Trend data is not available: the year-over-year change is N/A, the quarter-over-quarter change is N/A, and there are no historical values beyond the single current figure. Without any trend direction, it is impossible to assess whether the extreme negative margin is improving, worsening, or a one-time anomaly. This combination of an extremely low level and no observable trend signals high investment risk, as the company lacks even baseline profitability from its core operations. The metric strongly contradicts the overall NEUTRAL verdict because a -3346.4% gross margin is a critical red flag that merits a clear negative assessment.

Frequently Asked Questions

What does the Gross Margin tell investors about CRSP?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does CRSP's Gross Margin compare to its sector?

CRSP's Gross Margin of -3346.4% compares to a Healthcare sector median of 68.9%, placing it in the 0th percentile.

Who are CRSP's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: BLUE (68.4%), AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.